Clinical Trial Update: A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease [Phase 3]

View source ↗

Summary

Phase 3 trial comparing AZD9833 plus palbociclib versus anastrozole plus palbociclib in ER-positive, HER2-negative breast cancer patients who have not received …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• AZD9833 (AZD9833)
• Anastrozole (Anastrozole)
• Palbociclib (palbociclib)

Snippet

Sponsor: AstraZeneca | Conditions: ER-Positive HER2-Negative Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING